(firstQuint)Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002).

 Phase 1: To determine the maximum tolerated daily dose (MTDD) of KW 2449 when administered to subjects with AML who are not candidates for approved therapy.

 This was originally a Phase 1/Phase 2 study.

 However, a tolerable dose that had the potential for efficacy could not be identified in Phase 1.

 Therefore, Phase 2 was never conducted.

.

 Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)@highlight

To determine the maximum tolerated dose of KW-2449 in people with acute myelogenous leukemia who are not candidates for approved therapy.

 As well, the study will determine the response rate to KW-2449.

